90 related articles for article (PubMed ID: 26189002)
21. Evaluation of the proliferation marker MIB-1 in the prognosis of cutaneous malignant melanoma.
Hazan C; Melzer K; Panageas KS; Li E; Kamino H; Kopf A; Cordon-Cardo C; Osman I; Polsky D
Cancer; 2002 Aug; 95(3):634-40. PubMed ID: 12209757
[TBL] [Abstract][Full Text] [Related]
22. Prognostic groups of patients with stage I melanoma.
Kuehnl-Petzoldt C; Wiebelt H; Berger H
Arch Dermatol; 1983 Oct; 119(10):816-9. PubMed ID: 6614950
[TBL] [Abstract][Full Text] [Related]
23. E2F1 in melanoma progression and metastasis.
Alla V; Engelmann D; Niemetz A; Pahnke J; Schmidt A; Kunz M; Emmrich S; Steder M; Koczan D; Pützer BM
J Natl Cancer Inst; 2010 Jan; 102(2):127-33. PubMed ID: 20026813
[TBL] [Abstract][Full Text] [Related]
24. A therapeutic opportunity in melanoma: ErbB4 makes a mark on skin.
Settleman J
Cancer Cell; 2009 Oct; 16(4):278-9. PubMed ID: 19800573
[TBL] [Abstract][Full Text] [Related]
25. The magic of numbers: malignant melanoma between science and pseudoscience.
Weyers W
Am J Dermatopathol; 2011 Jun; 33(4):371-8. PubMed ID: 21478727
[TBL] [Abstract][Full Text] [Related]
26. Highly sensitive multivariable assay detection of melanocytic differentiation antigens and angiogenesis biomarkers in sentinel lymph nodes with melanoma micrometastases.
Vitoux D; Mourah S; Kerob D; Verola O; Basset-Seguin N; Baccard M; Schartz N; Ollivaud L; Archimbaud A; Servant JM; Revol M; Toubert ME; Podgorniak MP; Plassa F; Porcher R; Lebbé C
Arch Dermatol; 2009 Oct; 145(10):1105-13. PubMed ID: 19841396
[TBL] [Abstract][Full Text] [Related]
27. Epidermal growth factor receptor signaling in adenocarcinomas with bronchioloalveolar components.
Sarkaria IS; Zakowski MF; Pham D; Hezel M; Ebright MI; Chuai S; Venkatraman ES; Kris MG; Rusch VW; Singh B
Ann Thorac Surg; 2008 Jan; 85(1):216-23. PubMed ID: 18154814
[TBL] [Abstract][Full Text] [Related]
28. Altered expression of epidermal growth factor receptor ligands in tumor promoter-treated mouse epidermis and in primary mouse skin tumors induced by an initiation-promotion protocol.
Kiguchi K; Beltrán L; Rupp T; DiGiovanni J
Mol Carcinog; 1998 Jun; 22(2):73-83. PubMed ID: 9655251
[TBL] [Abstract][Full Text] [Related]
29. Prognostic factors in patients with localized primary cutaneous melanoma.
Mervic L
Acta Dermatovenerol Alp Pannonica Adriat; 2012; 21(2):27-31. PubMed ID: 23000937
[TBL] [Abstract][Full Text] [Related]
30. Dermatopathological indicators of poor melanoma prognosis are significantly inversely correlated with the expression of NM23 protein in primary cutaneous melanoma.
Ferrari D; Lombardi M; Ricci R; Michiara M; Santini M; De Panfilis G
J Cutan Pathol; 2007 Sep; 34(9):705-12. PubMed ID: 17696918
[TBL] [Abstract][Full Text] [Related]
31. Pathologic and clinical features influencing outcome of thin cutaneous melanoma: correlation with newly proposed staging system.
Finley JW; Gibbs JF; Rodriguez LM; Letourneau R; Driscoll D; Kraybill W
Am Surg; 2000 Jun; 66(6):527-31; discussion 531-2. PubMed ID: 10888127
[TBL] [Abstract][Full Text] [Related]
32. Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma.
Jensen TO; Schmidt H; Møller HJ; Donskov F; Høyer M; Sjoegren P; Christensen IJ; Steiniche T
Cancer; 2012 May; 118(9):2476-85. PubMed ID: 21953023
[TBL] [Abstract][Full Text] [Related]
33. Is DNA ploidy of prognostic significance in stage I cutaneous melanoma?
Gattuso P; Reddy V; Solans E; Kathuria S; Aranha GV; Jacobs HK; Walloch J
Surgery; 1990 Oct; 108(4):702-8; discussion 708-9. PubMed ID: 2218882
[TBL] [Abstract][Full Text] [Related]
34. Reduced expression of SRY-box containing gene 17 correlates with an unfavorable melanoma patient survival.
Lu J; Zhang G; Cheng Y; Tang Y; Dong Z; McElwee KJ; Li G
Oncol Rep; 2014 Dec; 32(6):2571-9. PubMed ID: 25310020
[TBL] [Abstract][Full Text] [Related]
35. Pathological staging of melanoma.
Elder DE
Methods Mol Biol; 2014; 1102():325-51. PubMed ID: 24258986
[TBL] [Abstract][Full Text] [Related]
36. EGFR gene copy number alterations in primary cutaneous malignant melanomas are associated with poor prognosis.
Rákosy Z; Vízkeleti L; Ecsedi S; Vokó Z; Bégány A; Barok M; Krekk Z; Gallai M; Szentirmay Z; Adány R; Balázs M
Int J Cancer; 2007 Oct; 121(8):1729-37. PubMed ID: 17594688
[TBL] [Abstract][Full Text] [Related]
37. A population-based validation of the American Joint Committee on Cancer melanoma staging system.
Gimotty PA; Botbyl J; Soong SJ; Guerry D
J Clin Oncol; 2005 Nov; 23(31):8065-75. PubMed ID: 16258105
[TBL] [Abstract][Full Text] [Related]
38. EGFR and cyclin D1 in nodular melanoma: correlation with pathohistological parameters and overall survival.
Katunarić M; Jurišić D; Petković M; Grahovac M; Grahovac B; Zamolo G
Melanoma Res; 2014 Dec; 24(6):584-91. PubMed ID: 25304234
[TBL] [Abstract][Full Text] [Related]
39. Activated leukocyte cell adhesion molecule (ALCAM/CD166): signaling at the divide of melanoma cell clustering and cell migration?
Swart GW; Lunter PC; Kilsdonk JW; Kempen LC
Cancer Metastasis Rev; 2005 Jun; 24(2):223-36. PubMed ID: 15986133
[TBL] [Abstract][Full Text] [Related]
40. Tumor necrosis is a prognostic factor in thick cutaneous melanoma.
Ladstein RG; Bachmann IM; Straume O; Akslen LA
Am J Surg Pathol; 2012 Oct; 36(10):1477-82. PubMed ID: 22982891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
